Incyte (INCY)
Technical, fundamental, and sentiment analysis with recent related videos.
INCY rates Bullish overall. The fundamental read is neutral: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 9.85); revenue is growing about 15.0% per year; net income is declining about 9.5% per year. The technical picture is neutral: price is 7.4% above the 200-day moving average; 4.6% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 75/100), based on 7 news articles from recent coverage.
Revenue 3-year avg +15.0%. Net income 3-year avg -9.5%.
Price vs 20DMA +0.6%. RSI 47.82. Bollinger state: Inside Bands.
Composite score 75/100 from the AI judge, based on 7 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamentals are Neutral: revenue has averaged 15.0 percent per year while net income has averaged -9.5 percent per year, and the negative profit trend keeps the badge at Neutral. Technical is Neutral: the price sits about 0.6 percent above the 20-day moving average (20DMA), the Relative Strength Index (RSI), a momentum reading, is 47.8, and the stock is inside the Bollinger Bands, a volatility channel. Sentiment is Bullish, composite 75/100, and that strong sentiment lifts the overall Bullish Gator rating to Bullish despite Neutral fundamental and technical readings.
Recent news: Coverage emphasizes Incyte's expanding oncology push, notably repeated reports of a Genmab collaboration to test INCB161734 with petosemtamab in KRAS G12D metastatic colorectal cancer and planned ESMO Madrid presentations; articles also note Incyte is co-funding and supplying its KRAS G12D inhibitor for a Genmab-run Phase 1/2 trial. Most sources frame these developments as potential commercial upside and pipeline expansion, although one piece raised valuation questions and cited a roughly 7.16% 30-day stock decline, tempering near-term sentiment.
Latest Videos
- No qualified videos yet.